---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-027354"
form_type: "8-K"
ticker: "MANE"
cik: "0001827635"
company_name: "Veradermics, Inc"
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:57:38.278446+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Veradermics' VDPHL01 meets all primary and key secondary endpoints in Phase 2/3 male hair loss trial

## Summary
- VDPHL01 achieved mean TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID) vs 7.3 for placebo at Month 6 (p<0.0001)
- 79.3% (QD) and 86.0% (BID) of patients reported improvement on AAIRS vs 35.6% placebo
- No treatment-related serious adverse events or cardiac adverse events of special interest observed
- Statistically significant separation from placebo observed as early as Month 2

## SEC filing metadata
- accession: 0001628280-26-027354
- form_type: 8-K
- ticker: MANE
- cik: 0001827635
- company_name: Veradermics, Inc
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/0001628280-26-027354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827635/000162828026027354/mane-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-027354
- JSON: https://secwatch.observer/filing/0001628280-26-027354.json
- Plain text: https://secwatch.observer/filing/0001628280-26-027354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.